Paul Bolno
Director at IVVD
Board
About Paul Bolno
Paul B. Bolno, M.D., MBA, was appointed as an independent director of Invivyd (IVVD) on September 22, 2025 and immediately joined the Compensation Committee . He is President and CEO of Wave Life Sciences (since 2013), where he oversaw the company’s IPO in 2015 and built the PRISM RNA medicines platform and pipeline . Previously, he held senior business development roles at GlaxoSmithKline (GSK) and served as Director of Research at healthcare private equity firm Two River LLC . Dr. Bolno earned his medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Wave Life Sciences | President & CEO | 2013–present | Oversaw IPO in 2015; led PRISM platform and pipeline development |
| GlaxoSmithKline (GSK) | VP Worldwide BD; Head Asia BD & Investments; Head Global Neuroscience BD; earlier VP BD Oncology | Pre‑2013 (dates not disclosed) | Member of Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team |
| Two River LLC | Director of Research | Pre‑GSK (dates not disclosed) | Healthcare private equity experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Invivyd (IVVD) | Independent Director; Compensation Committee member | Appointed Sept 22, 2025 | Listed among directors in Nov 2025 lock-up parties |
| ExpressionEdits | Chair of the Board; Independent Director | Appointed Dec 19, 2024 | Also referenced as serving on ExpressionEdits board in IVVD press release |
| Nucleic Acid Therapy Accelerator (NATA) | Chair of Scientific Advisory Group / Advisory Board | Ongoing (dates not disclosed) | Scientific governance and advisory role |
| Wave Life Sciences | President & CEO | 2013–present | Public company executive role |
Board Governance
- Committee memberships: Compensation Committee (appointed Sept 22, 2025) .
- Independence: Company disclosed no relationships or transactions requiring Item 404(a) related‑party disclosure for Dr. Bolno at appointment .
- Board leadership context: Chairperson of Invivyd’s Board is independent (Marc Elia), with committee structure and independence affirmed in 2025 proxy .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board retainer (cash) | $40,000 | Paid per Non‑Employee Director Compensation Policy |
| Compensation Committee member retainer (cash) | $5,000 | Annual committee member fee |
| Chair fees | Not applicable to Bolno (not a chair) | Policy: Audit Chair $15k; Comp Chair $10k; N&CG Chair $8k |
| Additional fees | None disclosed beyond retainers | Policy is retainer‑based; no meeting fees disclosed |
Performance Compensation
| Award | Grant date | Shares/Units | Strike/Terms | Vesting | Notes |
|---|---|---|---|---|---|
| Initial stock option (nonqualified) | Sept 22, 2025 | 100,000 options | Exercise price equals Nasdaq closing price on grant date; 10‑year term | 1/3 on first anniversary; 1/36 monthly thereafter to 3 years | Subject to 2021 Equity Incentive Plan |
| Annual director option (policy) | Each annual meeting | 50,000 options | Exercise price equals closing price on grant date; 10‑year term | Vests on earlier of first anniversary or next annual meeting | Pro‑rated if joining mid‑cycle |
| Change‑of‑control treatment | Policy basis | N/A | N/A | Director options accelerate upon change in control | Post‑termination exercise: 12 months if not for cause |
Note: Invivyd’s insider trading prevention policy prohibits hedging by directors and employees, supporting alignment with shareholders .
Other Directorships & Interlocks
| Company | Role | Public/Private | Potential Interlock/Conflict |
|---|---|---|---|
| ExpressionEdits | Chair of the Board; Independent Director | Private | No Invivyd transactions disclosed with ExpressionEdits; low conflict risk |
| NATA (UK) | Chair of Scientific Advisory Group / Advisory Board | Public sector initiative | Advisory role; no Invivyd transactions disclosed |
| Wave Life Sciences | President & CEO | Public (NASDAQ) | No IVVD–Wave dealings disclosed; Item 404(a) negative at appointment |
Expertise & Qualifications
- Medical and business credentials (MD; MBA), with clinical training in surgery and cardiothoracic research .
- Platform strategy and BD leadership across RNA therapeutics and big pharma (GSK oncology and neuroscience BD) .
- Governance roles beyond IVVD (ExpressionEdits chair; NATA advisory leadership) .
Equity Ownership
| Category | Detail |
|---|---|
| IVVD equity awards | Initial grant of 100,000 stock options on Sept 22, 2025; time‑based vesting; 10‑year term; strike price set at grant day close |
| Beneficial ownership (IVVD common) | Not disclosed at appointment; no Item 404(a) related‑party relationships with IVVD reported |
| Hedging/Pledging | Hedging prohibited under Insider Trading Prevention Policy; pledging not disclosed |
Governance Assessment
- Independence and conflicts: No relationships requiring Item 404(a) disclosure at appointment, and governance policies include formal related‑party review via Audit Committee . Low conflict signal despite external executive role, with no IVVD transactions reported with Wave or ExpressionEdits .
- Committee effectiveness: Placement on Compensation Committee adds operator perspective; committee uses an independent consultant (Alpine Rewards) and conducts quarterly executive sessions, supporting process quality .
- Alignment and incentives: Cash compensation is modest ($40k board, $5k committee) with equity options subject to time‑based vesting, change‑of‑control acceleration, and hedging prohibition—indicative of standard biotech director alignment .
- Engagement signals: Appointed in late 2025; included among directors in offering lock‑up parties in Nov 2025, indicating participation in capital markets events and alignment with financing processes .
Red flags
- None disclosed: No related‑party transactions, no attendance concerns, and no pay anomalies tied to discretion or repricing noted for director awards .
Additional context
- Invivyd board structure and independence affirmed in 2025 proxy, with independent Chair and active committee oversight of risk, compensation, and governance .